Online Only Articles

Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden
Haematology and Coagulation Section, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden;Hematology Section, Department of Medicine, NU Hospital Group, Uddevalla, Sweden
Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden
Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden
Haematology and Coagulation Section, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Haematology and Coagulation Section, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden;Hematology Section, Department of Medicine, NU Hospital Group, Uddevalla, Sweden
Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden
Vol. 101 No. 4 (2016): April, 2016 https://doi.org/10.3324/haematol.2015.138958